REG - Novacyt S.A. - Publication of Annual Report and AGM voting

Novacyt SAAnnouncement

26/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230526:nRSZ7294Aa&default-theme=true

RNS Number : 7294A  Novacyt S.A.  26 May 2023

Novacyt S.A.

 

("Novacyt", the "Company" or the "Group")

 

Publication of Annual Report and AGM voting

 

Paris, France and Eastleigh, UK - 26 May 2023 - Novacyt (EURONEXT GROWTH:
ALNOV; AIM: NCYT), an international specialist in clinical diagnostics,
announces that the Company's Annual Report and Accounts ("Annual Report") for
the year ended 31 December 2022 has been published and uploaded to the
Company's website. The Annual Report has been posted to all shareholders that
hold ordinary shares through CREST Depository Interests (CDIs).

 

The Company's Annual General Meeting ("AGM") will be held exclusively as an
open online meeting at 1pm BST/2pm CEST on Thursday, 15 June 2023. As usual,
and in accordance with French corporate law, the AGM comprises both ordinary
and extraordinary resolutions. All materials can be found at
www.novacyt.com/investors (http://www.novacyt.com/investors) .

 

Shareholders are strongly encouraged to submit their votes in advance, in
accordance with the instructions in the Notice of the AGM.

 

Under French law, for the AGM and EGM meetings to be quorate at the first
attempt, shareholders representing at least 20% of the share capital and
voting rights, on ordinary resolutions, and 25% of the share capital and
voting rights, on extraordinary resolutions, must be present, represented or
have voted in advance under the conditions set out below.

 

Shareholders can vote in advance of the AGM by:

 

·      Downloading a copy of the proxy voting form from the website
www.novacyt.com/investors (http://www.novacyt.com/investors) , completing it
and returning it together with evidence of their shareholding which must be in
the form of a share certificate (attestation), either by post to the following
address: 6 avenue de Provence 75452 Paris Cedex 09, or via email to the
following address: serviceproxy@cic.fr (mailto:serviceproxy@cic.fr) , or
investor.relations@novacyt.com (mailto:investor.relations@novacyt.com) ,  no
later than 12 June 2023 inclusive.

·   Voting on-line using the Votaccess portal
http://www.actionnaire.cic-marketsolutions.eu
(http://www.actionnaire.cic-marketsolutions.eu)  if securities held on
Euronext Growth are registered with any of the following banks: CIC, Natixis,
Société Générale, Caceis, Crédit Agricole, BP2S, BNP Retail, Bourse
Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank, Deutsche Bank,
Bank of New York or JP Morgan. The Votaccess portal will be open from 26 May
2023 to 14 June 2023 2pm BST/3pm CEST.

·     Voting on-line via a broker, nominee, bank or authorised
intermediary. Many intermediaries in the UK such as Hargreaves Lansdown are
now using the Broadridge ProxyVote on-line voting portal.

 

Shareholders can register for the AGM and access the online meeting by
visiting www.novacytagm23.eventcaster.co.uk
(http://www.novacytagm23.eventcaster.co.uk) . Registrations must be
accompanied by formal evidence of shareholding.

 

Following registration approval, shareholders will be able to virtually attend
the AGM and vote online during the meeting if they wish, providing formal
evidence of holding has been provided prior to the meeting.

 

Shareholders who have already voted (through a proxy, via their broker,
nominee, bank, authorised intermediary, Votaccess portal or Broadridge
ProxyVote) will be allowed to attend the AGM but will not be able to vote
twice.

 

Following the meeting, a recording of the AGM will be available on the
Company's website at www.novacyt.com/investors
(http://www.novacyt.com/investors) .

 

- End -

 

 

Contacts

Novacyt SA

James Wakefield, Non-Executive Chairman

James McCarthy, Acting Chief Executive Officer

+44 (0)2380 748830

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis (Joint Broker)

Freddie Barnfield / Duncan Monteith / Jack McLaren

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) ;
y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

 

Walbrook PR

Paul McManus/ Stephanie Cuthbert/ Anna Dunphy

+44 (0)20 7933 8780

novacyt@walbrookpr.com (mailto:novacyt@walbrookpr.com)

 

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio
of in vitro and molecular diagnostic tests for a wide range of infectious
diseases, enabling faster, more accurate, accessible testing to improve
healthcare outcomes. The Company provides customers with a seamless
sample-to-result workflow using its integrated and scalable
instrumentation/solutions. The Company specialises in the design, manufacture,
and supply of real-time PCR kits, reagents and a full range of laboratory and
qPCR instrumentation for molecular biology research and clinical use. Novacyt
offers one of the world's most varied and comprehensive range of qPCR assays,
covering human, veterinary, biodefence, environmental, agriculture and food
testing.

 

Novacyt is headquartered in Vélizy in France with offices in Stokesley and
Eastleigh, UK, and is listed on the London Stock Exchange's AIM market
("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDELFLXELFBBX